Top Stories
Arcera gains exclusive rights across emerging markets, including Latin America and the Middle East.
The agreement will see the companies combine their resources to hunt for small-molecule drug candidates targeting oncology.
In conjunction with the move, nChroma Bio will undertake a restructuring, which news sources suggested will cut the biotech's workforce by around half.
Chief medical officer Eric Hughes will step down, to be replaced on an interim basis by David Gardiner, who heads innovative medicines and clinical development, until a permanent successor is found.
The agency will make a decision on sonesitatug vedotin in the second quarter of 2027.
Conference News
With additional patients and longer follow-up, the combination of RASONQUE plus gemcitabine and nab-paclitaxel demonstrated deep and durable responses in the first-line treatment settingResults suppor...
This year's ObesityWeek meeting didn't come with much in the way of dramatic data reveals, but presentations point to a changing undercurrent in the way doctors are treating their patients with obesity.
Summit’s FDA climb just got steeper with ivonescimab snubWhile the FDA's rejection of Summit Therapeutics and Akeso's ivonescimab didn't come as a complete surprise for those paying attention, the com...
Key milestone in GE HealthCare’s adaptive Phase 2/3 LUMINA clinical trial, with Phase 2 results meeting primary endpoint, showing mangaciclanol and market-leading gadolinium-based agent, gadobutrol, h...
November 19, 2026 Alyssum Therapeutics Inc., a clinical stage biopharmaceutical company developing a pipeline of first in class therapeutics through a patented technology platform, today announced a l...





